The American Diabetes Association and European Association for the Study of Diabetes (ADA/EASD) guidelines acknowledge that “CSII is a less commonly used and more costly alternative” to basal-bolus therapy in patients with T2DM.  The Opt2mise was a robust study intended to clarify the role of CSII in patients with T2DM.

The American Diabetes Association and European Association for the Study of Diabetes (ADA/EASD) guidelines acknowledge that “CSII is a less commonly used and more costly alternative” to basal-bolus therapy in patients with T2DM. The Opt2mise was a robust study intended to clarify the role of CSII in patients with T2DM.

The American Diabetes Association and European Association for the Study of Diabetes (ADA/EASD) guidelines acknowledge that “CSII is a less commonly used and more costly alternative” to basal-bolus therapy in patients with T2DM.&nbsp; The Opt2mise was a robust study intended to clarify the role of CSII in patients with T2DM.

Insulin Delivery in Type 2 Diabetes: To Pump or Not to Pump?

We explore the evidence that informs ambulatory care pharmacy practice. Check out our website &amp; podcasts, &amp; consider submitting a commentary!

Medicine

Health & Fitness

We explore the evidence that informs ambulatory care pharmacy practice. Check out our website & podcasts, & consider submitting a commentary!

Share Insulin Delivery in Type 2 Diabetes: To Pump or Not to Pump?

Sign up to save your podcasts

Insulin Delivery in Type 2 Diabetes: To Pump or Not to Pump?

Insulin Delivery in Type 2 Diabetes: To Pump or Not to Pump?